Myung Hee Chang and Jeeyun Lee contributed equally to the work presented here.
Prognostic role of insulin-like growth factor receptor-1 expression in small cell lung cancer
Article first published online: 17 NOV 2009
© 2009 The Authors. Journal Compilation © 2009 APMIS
Volume 117, Issue 12, pages 861–869, December 2009
How to Cite
CHANG, M. H., LEE, J., HAN, J., PARK, Y. H., AHN, J. S., PARK, K. and AHN, M.-J. (2009), Prognostic role of insulin-like growth factor receptor-1 expression in small cell lung cancer. APMIS, 117: 861–869. doi: 10.1111/j.1600-0463.2009.02545.x
- Issue published online: 17 NOV 2009
- Article first published online: 17 NOV 2009
- Received 4 June 2009. Accepted 13 July 2009
- Small cell lung cancer;
- insulin-like growth factor receptor-1;
- prognostic factor
Chang MH, Lee J, Han J, Park YH, Ahn JS, Park K, Ahn M-J. Prognostic role of insulin-like growth factor receptor-1 expression in small cell lung cancer. APMIS 2009; 117: 861–9.
Insulin-like growth factor receptor-1 (IGFR-1) is a cellular membrane receptor which is overexpressed in many tumors and seems to play a critical role in anti-apoptosis. The insulin-like growth factor binding protein-3 (IGFBP-3) is known as a growth suppressor in multiple signaling pathways. The aim of this study was to determine IGFR-1 and IGFBP-3 expression in small-cell lung cancer (SCLC) and analyze the prognostic value in patients with SCLC. We analyzed IGFR-1 and IGFBP-3 expression in 194 SCLC tissues by immunohistochemical staining. Correlative analyses between IGFR-1 and IGFBP-3 expression in SCLC and clinicopathologic factors were performed. A total of 117 patients had extensive disease (ED) (60.3%) and 77 had limited disease (39.7%). With the median follow-up duration of 49.5 months (24–82 months), the median progression-free survival (PFS) and overall survival (OS) were 7.2 months [95% confidence interval (CI): 6.4–8.0 months] and 14.4 months (95% CI: 12.7–16 months), respectively. IGFR-1 expression was observed in 154 of the 190 tumor tissues, whereas there was no IGFBP-3 expression. Multivariate analysis showed that stage (p < 0.001), response rate (p < 0.001), and lactate dehydrogenase (LDH) levels (p < 0.001) were the independent prognostic factors for PFS, and age (p = 0.014), LDH level (p < 0.001), and stage (p < 0.001) for OS. The IGFR-1 positivity was not associated with PFS or OS in the entire cohort. Subgroup analysis revealed that OS was significantly longer in patients with IGFR-1-positive tissue than IGFR-1-negative tissue in SCLC-ED (p = 0.034). These results suggest that IGFR-1 expression may be useful as a prognostic marker in patients with SCLC-ED.